

Opioid Abatement Council Meeting

June 23, 2023 12:00pm – 3:00pm CDT West Tennessee Healthcare City/ County Boardroom

Jackson, TN

Opioid Abatement Council Meeting

- Thank you for joining the Council meeting
- We are recording the meeting
 - If you are **Guest**, please turn off your camera and mute yourself
 - If you are a **Council member**, please leave your camera on and mute yourself



Introductions & Gratitude

- Dr. Stephen Loyd Chair, Opioid Abatement Council
- Marie Williams Commissioner, Tennessee Department of Mental Health and Substance Abuse Services





Ethics Discussion





Division of General Counsel

6/21/2023

OPIOID ABATEMENT COUNCIL LEGAL GUIDANCE Representation, Ethics, Open Meetings, & Open Records

Legal Services. Pursuant to T.C.A. 33-11-104(a)(1)), "[t]he department shall serve as staff to the council...." Accordingly, the Tennessee Department of Mental Health and Substance Abuse Services' Division of General Counsel (DGC) will provide legal services to the Opioid Abatement Council (OAC) so long as doing so does not create a conflict of interest with the State of Tennessee or the department. The council may meet in closed executive session to receive legal advice (T.C.A. 33-11-103(j)). However, matters covered in open sessions are not confidential as there is no expectation of privacy.

Ethics Guidelines. The council was statutorily created by the State of Tennessee to direct the disbursement of funds held in the state's opioid abatement trust fund. Accordingly, it is expected to meet the highest standards of state ethics and transparency. The department will apply Governor Bill Lee's Executive Order No. 2 when addressing ethics issues. It requires that the business of the state be open and transparent and that those conducting the business of the state will not take any action which could result in or create the appearance of their having a conflict of interests, seeking private gain, showing preference, impeding government efficiency, losing impartiality, or making decisions outside of official channels or which may otherwise cause the public to lose confidence in the integrity of government. The conflicts of interest statement signed by council members requires them to disclose anything which could be seen as a potential violation of these ethical standards.

Open Meetings Act. "Meetings of the council must comply with the open meeting requirements of title 8, chapter 44. Notwithstanding the open meeting requirements of title 8, chapter 44, the council is permitted to meet in a closed executive session for the purpose of obtaining advice from counsel and discussing personnel-related issues in addition to any other purposes allowed by title 8, chapter 44." (T.C.A. 33-11-103(j)). This requires, in part, that (1) council members shall not conduct the business of the council (e.g., deliberations, discussions, etc.) outside of an official meeting of the council, (2) public meetings (T.C.A. 8-44-101 et seq., as amended by Public Chapter 300 (2023)). Executive Order No. 2 further requires avoiding any action which could call into question the integrity or impartiality of the council. Accordingly, council members should not discuss the business of the council or do anything which may be considered the business of the council outside of meetings of the council. Questions about meetings, administrative matters, etc., should be referred to the council's website or Executive Director.

Open Records Act. "Records of the council are deemed to be public records for purposes of the open records law, compiled in title 10, chapter 7, subject to the confidentiality provisions of § 10-7-504 and other laws or doctrines." (T.C.A. 33-11-103(k)).

Privacy. The council must conduct meetings and handle any information, documentation, or records in a manner which complies with privacy laws (e.g., HIPAA, 42 CFR Part 2, T.C.A. 33-3-103).

Removal. Pursuant to T.C.A. 33-11-103(f), "[t]he respective appointing authority may remove a member for failure to attend at least one-half (\underline{M}) of the scheduled meetings in any one-year period or for other cause." Accordingly, the respective appointing authority makes determinations on the conduct of individual council members.





E X E C U T I V E O R D E R BY THE GOVERNOR

No. 2

AN ORDER CONCERNING ETHICS POLICIES APPLICABLE TO, AND ETHICS DISCLOSURES REQUIRED OF, EXECUTIVE BRANCH EMPLOYEES

WHEREAS, establishing, communicating, complying with, and enforcing a robust and comprehensive ethics policy within the Executive Branch of the State of Tennessee is essential to maintaining public trust in government and ensuring the proper performance of government; and

WHEREAS, disclosure is an indispensable element of an effective ethics policy; and

WHEREAS, this Administration is committed to simplifying and streamlining government processes, systems, and policies to a point understandable by Tennessee citizens;

WHEREAS, this Executive Order No. 2 underscores, expands, and enhances the commitment of this Administration to the highest standards of ethics and transparency by employees of the Executive Branch.

NOW THEREFORE, I, Bill Lee, Governor of the State of Tennessee, by virtue of the power and authority vested in me by the Tennessee Constitution and the laws of Tennessee, do hereby direct and order that:

- Except where otherwise noted, this Order applies to the following employees of the Executive Branch of the State of Tennessee: the Governor, members of the Governor's staff, members of the Governor's Cabinet, and all other Executive Branch employees.
- Each employee shall avoid any action, whether or not specifically prohibited by statute, regulation, or this Order, which might result in or create the appearance of:
 - a. Using public office for private gain;
 - b. Giving preferential treatment to any person;
 - c. Impeding government efficiency or economy;
 - d. Losing complete independence or impartiality:

Please find the complete Executive Order #2:

https://www.tn.gov/content/dam/tn/hr/ policy/workforce/Executive%20Order% 202.pdf

TENNESSEE OPIOID ABATEMENT COUNCIL EXECUTIVE ORDER NUMBER 2 STATEMENT

I, (print name)_____, member of the Tennessee Opioid Abatement Council (Council), hereby certify the following:

- 1. I have received a copy of Governor Bill Lee's Executive Order No. 2, dated January 24, 2019.
- I understand and agree to abide by Executive Order No. 2 regarding my membership on the Council and any actions taken by the Council.
- 3. Regarding Executive Order No. 2, I further understand and agree that:
 - References to employees shall apply to Council members, including myself, regarding all activities, actions, etc., of the Council;
 - b. References to financial interests in section 3.a. applies to any contractual or other financial interests related in any way to the Council or Tennessee's Opioid Abatement Fund;
 - References to the Executive Branch or to the state department or agency in which the individual is employed applies to the Council for this purpose;
 - References to Chief Ethics Officer will be read as references to the Council's Chair and Executive Director (e.g., ethics related disclosures and record keeping);
 - e. The disclosure forms referenced in section 5 of Executive Order No. 2 shall not be used and forms adopted by the Council will be used in their place (e.g., this form); and
 - f. Any enforcement issues, such as referenced in section 7 of Executive Order No. 2, shall be directed to the appointing authority who appointed the Council member.
- I also hereby certify that I have read, understand, and signed the Tennessee Opioid Abatement Council Conflict of Interest Statement.

Council Member Signature

Date

TENNESSEE OPIOID ABATEMENT COUNCIL INTEREST DISCLOSURE

The purpose of this form is to disclose any potential financial conflict of interest you may have related to your serving as a council member on the Tennessee Opioid Abatement Council (Council) or related to the Tennessee's Opioid Abatement Fund (Trust Fund).

Your conduct is subject to the guidelines established by the Executive Order Number 2 Statement, with its attached Executive Order No. 2, and the Conflict of Interest Statement. Both of which you must sign to be a member of the Council. You are not allowed to have a conflict of interest or even the appearance of a potential conflict <u>in regard to</u> anything you do related to the Council or the Trust Fund. The respective Council member's appointing authority will make the final decision regarding any conflict issue.

You must fill out the form below disclosing any potential conflict of interests you may have related to the Council or Trust Fund. Alternatively, you may bring any potential conflicts you are presently aware of to the attention of your appointing authority and the Council's Chair and Executive Director. However, this form will still need to be filled out and provided to the Executive Director before you assume any duties as a member of the Council.

I, (print name)______, hereby affirm that the answers given to the following questions are true and accurate to the best of my knowledge and belief and, further, that I will immediately notify the Council's Chair and Executive Director of any changes which would require me to amend the following responses.

Regarding the Council and/or Trust Fund:

 Do you or any of your family members (i.e., parents, siblings, children, or spouse), directly or indirectly, own any shares or have any financial investment or interest in any form in any business, corporation, or other entity which has or may apply for funds or any other benefit from the Council or Trust Fund or which has or may contributed funds into the Trust Fund?

a. ____ No.

b. ____ Yes. Please explain:

2. Are kou or any of your family members employed by, hold an office or position with (e.g., board member), or have any official relationship to any non-profit enterprise, for-profit enterprise, business, corporation, or any other entity which has or may apply for funds or any other benefit from the Council or Trust Fund or which has or may contributed funds into the Trust Fund?

a. ____ No.

b. ____ Yes. Please explain:

3. Have you or any of your family members applied for funds or any other benefit from the Council or Trust Fund or do you have any reason to think <u>you</u> or they will in the future?

a. ____ No.

b. ____ Yes. Please explain:

4. Do or have you, any of your family members, or any business partners ever done any form of lobbying for any entity which has or may apply for funds or any other benefit from the Council or Trust Fund or which has or may contributed funds into the Trust Fund?

a. ____ No.

b. ____ Yes. Please explain:

5. Are you or any of your family members employed by or have any financial interest in an entity which has done or may do any form of lobbying for any person or entity which has or may apply for funds or any other benefit from the Council or Trust Fund or which has or may contributed funds into the Trust Fund?

a. ____ No.

b. _____ Yes. Please explain:

Review & Approval of Minutes

• Dr. Stephen Loyd

Minutes from:

- February 27, 2023
- March 9, 2023 (virtual)
- April 3, 2023 (virtual)
- May 24, 2023 (virtual)



Our Why - Jonah







Administrative Updates

- OAC Binders
- OAC Website
- Travel expense form must be turned in by 6/27
- Technology and emails
 - Requesting your assistant's contact info & your cell number
 - Please check your "junk email" and make sure you are receiving our emails
- Community Grants application update
- County payments and reports update
- New positions update on contract position



State employee vs. Contract position

We have researched the possibility of hiring the 2 Grants Analysts positions via contract, rather than creating 2 state employee positions:

State Employee	Contract Positions
Positions budgeted for \$70,754 (\$141,508 for 2 positions)	The hourly rate for a grants analyst is \$67. Using 37.5 (hours) x 4.3 (avg # of wks in a month) that would come out to \$10,803.75 per month or \$129,645
May take 2 months to hire	The process may take 1 month to hire
OAC Office interviews and selects candidate	OAC Office interviews and selects candidate



Fiscal Update



Opioid Abatement Trust Fund

- Each meeting, the OAC Office will share the current monthly Opioid Abatement Trust Fund Statement
- Please note that the information is current to date the statement was created



April Opioid Abatement Trust Fund Statement

Description	Cash
McKinsey Deposit 3.31.2021	12,613,210.59
McKinsey Deposit 4.19.2022	651,080.54
Distributor Settlement 8.12.2022 - AmerisourceBergen Drug Corp., McKesson Corp., Cardinal Health, Inc. and AmerisourceBergen Corp.	14,914,621.88
Distributor Settlement 10.17.2022 - AmerisourceBergen Drug Corp., McKesson Corp., Cardinal Health, Inc. and AmerisourceBergen Corp.	15,674,540.42
Distributor Settlement 11.22.2022 - AmerisourceBergen Drug Corp., McKesson Corp., Cardinal Health, Inc. and AmerisourceBergen Corp.	59,709,854.06
Distributor Settlement 2.09.2023 - Mallinckrodt	4,112,865.67
McKinsey Deposit 4.03.2023	651,080.54
FY 22 Interest Earned	27,134.50
FY 23 Interest Earned	1,886,329.45
County Distributions	(31,425,152.77)
Totals	78,815,564.88





Guidance on Web Postings

Guidance on Web Postings

 In an effort to ensure that all relevant information and data is posted on the Opioid Abatement Council's website, the Office is asking the Council to approve the development of Guidance on Web Postings.

 Perhaps include in the policy information from those public records that we can reasonably anticipate that the community may show interest.



Discussion & Decision Point

 Does the Council approve the OAC Office creating a Guidance for Web Postings for the Council to review in a future meeting?







Recovery Housing Definition

- The Standards & Metrics Subcommittee met on 5/31 & 6/13
- We reviewed the Safe Act and discussed the relevance and legal implications with Sam Boukli, OAC Servicing Attorney
- The definition is modeled on language from the Safe Act



Working definition for OAC to review

• The Subcommittee presents this working definition for the OAC to review and discuss:

If applying for recovery housing funding, applicants will be required to show current certification and/or recognition status through a state and/or nationally recognized recovery residence standards organization, any affiliate of any nationally recognized recovery residence standards organization OR the applicant must be currently funded by the State of Tennessee or a federal department or agency to support and/or create a recovery residence.



Discussion & Decision Point

 Does the Council approve the definition of Recovery Housing for the Qualified Applicant List for the Community Grant Applications?







Needs Assessment Annual Report to the OAC



Requirement to hear from the Planning & Policy Council


T.C.A. 33-11-105(b)

 Before rendering decisions regarding the disbursement of funds, the council shall receive input from the department's statewide planning and policy council's need assessment process, which is conducted with the assistance of seven (7) regional planning and policy councils



TDMHSAS Statewide Planning & Policy Council

- Councils and Committees consist of mental health and substance abuse service providers, consumers, family members, advocates and other stakeholders.
- 7 Regional Councils and 1 Statewide Council, which administers/partners with several committees, including the Adult Committee, the Children's Committee, and Consumer Advisory Board.
- All Councils and Committees meet quarterly





Needs Assessment

- The Tennessee Department of Mental Health and Substance Abuse Services completes an annual assessment of need in order to prioritize programming.
- TDMHSAS ensures that the most relevant needs are prioritized by asking the Statewide and Regional Planning and Policy Councils to complete an annual Needs Assessment.
- Each Spring, the seven Regional Planning and Policy Councils as well as the Statewide Planning and Policy Council's Committees (Adult, Children's, and Consumer Advisory Board) work independently to identify and prioritize up to three mental health and three substance abuse needs.
- Here is the link to the 2023 Needs Assessment Survey Summary <u>https://www.tn.gov/content/dam/tn/mentalhealth/planning/FINAL%202023%20NA%20Summary.pdf</u>

The process helps in two ways:

- 1. The planning and policy councils help identify regional needs and assets in order to influence the mental health and substance abuse system; and,
- 2. It provides a method for the Department to target limited state resources to more effectively and efficiently meet the identified needs.

2023 Needs Assessment – Multiple Region Needs

In 2023, multiple regions identified identical/similar substance abuse-related needs:

- Increase funding/number of and access to residential & detox beds for adults and children (identified in 2016, 2017, 2018, 2019, 2020, 2021 and 2022)
 - Regional Councils 1, 2, 5, 6, 7 & Children's Committee
- Increase prevention and school-based programs for at-risk youth (identified in 2017, 2018, 2019, 2020, 2021 and 2022)
 - Regional Councils 3, 7
- Increase recovery housing, including Medication Assisted Treatment (MAT) (identified in 2016, 2017, 2018, 2019, 2020, 2021 and 2022)
 - Regional Councils 2, 4, 5, 6 & Adult Committee

Transportation

Regional Council 1, Consumer's Advisory Board (CAB)

*The TDMHSAS Planning and Budget Committee of the Statewide Planning and Policy Council acknowledges that the department has created or expanded programs to address these needs in the past and on an ongoing basis.



Work of the Council

Dr. Stephen Loyd	Recovery Eco System Medication Assisted Treatment (MAT)
Dr. Clay Jackson	Palliative Care & Pain Medicine
Tommy Farmer	Law Enforcement and Diversion
Karen Pershing	Prevention
Lisa Tipton	Treatment with emphasis on Social Determinants of Health





Unintended Consequences.

W. Clay Jackson, MD, DipTh

Pain, Policy, Pills, and Palliation West Cancer Center Director, Palliative Medicine University of TN College of Medicine Depts. of Family Medicine and Psychiatry @mydocjackson



Know the difference in acute vs. chronic pain with respect to the biopsychosociospiritual model

Be able to explain how administrative categories of **'cancer pain'** and Appreciate ways in which the response to the 'opioid epidemic' has led to **unintended consequences**


Contemplate a **'middle and margins'** strategy to improving public health vis-à-vis the role of opioids in society








The Graph that Staunched a Thousand Scripts



¹ Kolodny A, Courtwright DT, Hwang CS, *et al*. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. *Annu Rev Public Health* 2015;36:559-574.



Strategies to Reduce Overprescription




<u>Federal</u>

- Criminal prosecution of illicit prescribers via Controlled Substances Act
 - 32 TN clinicians charged in 2019
 - limited by Ruan v
 United States (2022)
- Reclassification of

<u>State</u>


- Complaints-based regulatory intervention (*e.g.*, state boards)
- Formative regulatory oversight (*e.g.*, pain clinic registration; 2012)
- Establishing prescription guidelines (2012)

Potential Doctor and Pharmacy Shoppers Identified in CSMD, 2015-2022*




* 1) Patients that filled controlled substance prescriptions obtained from 5 or more different prescribers at 5 or more dispensers within 90 days; 2) Excluding prescriptions reported from VA pharmacies.


Pain Management Clinics – Number in TN



A "pain management clinic" is a privately owned clinic in which the majority of patients are prescribed or dispensed opioids, benzos, etc. for 90 days or more in a 12-month period for non-malignant pain.

TN







MME of Opioids Dispensed and Reported to CSMD, 2015-2022*

MME Dispensed to All Patients MME Dispensed to TN Patients

* 1) Excluding prescriptions reported from VA pharmacies; 2) Excluding buprenorphine products.



United States, methamphetamine overdose deaths per 100,000 people




Time for New Models?

- Pain is a symptom, not a sign¹
 - Quantification of subjectivity does not objectivity make
 - There is no algometer
- Chronic pain is not acute pain with Groundhog Day syndrome
 - Acute pain is predominantly a biologic phenomenon
 - Chronic pain is predominantly a psychosociospiritual phenomenon²
 - 'All symptoms are a product of an inferential process' utilizing³
 - Sensory inputs
 - Prior experience
 - Contextual clues

¹ Ballantyne JC, Sullivan MD. NEJM 2015; 373(22):2098-99. ² Hashmi JA, Baliki MN, Huang L, *et al. Brain* 2013; 136:2751-68.


³ Ongaro G, Katpchuk TJ. Pain 2019; 160: 1-4.





Acute Pain Chronic Pain





Maletic V, Raison CL. Front Biosci. 2009;14:5291-5338.

Freud was right—you should choose your parents well

- Adverse childhood experiences contribute downstream risks
 - Chronic pain¹
 - Substance use disorders²
 - Mental illness³
- Likely high levels of inflammation, due to epigenetic effects, link multiple medical disorders in those exposed to ACE's⁴

¹ Edwards RR, Dworkin RH, Sullivan MDm Turk DC, Wasan AD. *J Pain*. 2016; 17(9 Suppl): T70–T92.
 ² Wolitzky-Taylor K, Sewart A, Vrshek-Schallhorn S. *J Youth Adolesc*. 2017; 46(1): 15–27.
 ³ Danese A, Moffitt TE, Harrington H, *et al*. *Arch Pediatr Adolesc Med*. 2009; 163(12): 1135–1143.
 ⁴ Maletic V, Raison CL. *Front Biosci*. 2009;14:5291-5338.



mental Health Matters

- Correlation between mental illness, chronic pain is bidirectional¹
 - (+) Mental illness: 2x OR of chronic pain
 - (+) Chronic pain: 2x OR of mental illness
 - Of patients on chronic opioids, 47% use benzodiazepines (BZD's) also²
 - Boxed warning from FDA regarding co-prescribing (Aug 2016)
- Mental illness increases risk of misuse, overdose
- Opioid users with anxiety 5x more likely to misuse ¹ Bondesson E, Pardo FL, Stigmar K, *et al. Eur J Pain*. 2018; doi:10.1002/ejp.1218.

² Zah V, et al. Use of co-medications in chronic pain patients on opioids. AIPM 28th Ann Mtg; San Diego (CA); Oct 2017.

³ Feingold D, et al. Gen Hosp Psychiatry 2017; 47: 36-42.



The Bottom Line on Prescription

Opioids

- The overwhelming majority of patients exposed to opioids (98.7%) do <u>not</u> progress to long-term use within 18 mos¹
- Addiction occurs in a sizeable minority of chronic pain patients who use opioids (8%)²
- Non-medical use of prescription opioids may lead to abuse of heroin—but not often (< 4% in 5 years)³
- Long-term oral opioids are neither intractable nor infallible⁴
 - ~40% reduction in pain scores (7 studies; N=1504)
 - 33% of patients discontinued, owing to adverse events



¹ Kroenke K, Cheville A. *JAMA*. 2017; 317(23):2365-2366.

Quinn PD, Hur K, Chang Z, et al. Pain 2017;158(1):140-148.

² Volkow ND, McLellan T. *NEJM* 2016; 374(13):1253-63.

³ Muhuri PK, Gfroerer JC, Davies MC. SAMHSA CBHSQ Data Review; August 2013; 16.

⁴ Noble M, et al. J Pain Symptom Manage 2008; 35:214e228.



- Subjectivity does not become objectivity because you have a metric
 - Complex problems do not admit to simple solutions
 - The Law of Unintended Consequences is a tough customer
 - Overprescribing facilitated a crisis, but did not cause it; therefore, right-sizing (or under-sizing) prescribing will not solve it
 - Biology is a great place to start... but a poor place to finish
 - Patients should precede protocols, but not principles




What is Palliative Care?

- <u>Management of</u> <u>symptoms</u>, chiefly in patients with <u>advanced</u> <u>disease</u> in whom <u>medical</u> <u>recovery is not expected</u>
- Latin pallus: 'cloak'





What Does Palliative Care Do?





Prevalence of Pain in Cancer Patients

• 2016 meta-analysis:



- Included advanced stage, palliative patients
- Broader range of malignancies
- 2021 meta-analysis²: 40%
 - Included patients in active treatment, up to 90d after tx
 - Only included lung, breast patients (with intent to cure)
 - Excluded Stage IV, palliative patients
- 75-80% of advanced cancer report pain³

¹ Van Den Beuken-Van Everdingen MHJ, et al. J Pain Symptom Manage 2016;51:1070-1090.
 ² Evenepoel M, et al. J Pain Symptom Manage 2022;63(3) e317-e335.
 ³ van den Beuken-van Everdingen MH, et al. Ann Oncol 2007;18:1437-1449.



A National Survey of 5,139

Survivors

- Pain prevalence in cancer patients
 - 60% in active treatment²
 - 35% in survivors (16% high-impact pain)³
- Opioid use, misuse in last 12 mos:
 - No cancer: 31% 4.3%
 - Recent cancer (< 12 mos) 54%
 3.5%
 - Remote cancer (> 12 mos) 39%
 3.0%
 - Opioid use back to baseline at year 6 of survivorship

¹Jairam V, *et al. JAMA Network Open* 2020;3(8)e2013605 ²van den Beuken-van Everdingen MH, *et al. Ann Oncol* 2007;18(9):1437-1449 ³Jiang C, *et al. JAMA Oncol* 2019;5(8):1224-1226



A National Survey of 5,139

Survivors

- Cancer survivors are more likely to <u>use</u> opioids, but <u>not</u> more likely to <u>misuse</u> opioids, than the non-cancer population
- Cancer survivors are <u>less</u> likely to use opioids than patients with other active, chronic diseases
 - Cancer survivorship 43%
 - Cirrhosis 56% - COPD 53%
 - CKD 51%
- Among chronic disease patients, rates of misuse *lowest* among cancer survivors (3.1%), except for Type 2 DM (2.9%)
- Risk factors for opioid *misuse* (among survivors)
 - Young age (35-64 yo vs. >64 yo)
 OR 7.1
 - EtOH use OR 3.2
 - Non-opioid SUD OR 14.8



About that line between cancer pain & chronic pain...

- ASCO defines chronic pain as >90d¹
- Opioid use that begins upon treatment, and extends >90d beyond treatment completion, would seem to be an appropriate definition of prolonged pain in cancer patients²
- Chronic pain is common in cancer survivors³
 - 35% of survivors have chronic pain (5.4M US pts)
 - 16% have high-impact chronic pain (2.5M US pts)
 - HICP: chronic pain with major activity restriction
 - Higher incidence with lower SES factors
 - Higher incidence in certain cancers
 - Bone, kidney, throat/pharynx, uterine
 - No correlation with time from diagnosis

¹Paice JA, *et al. J Clin Oncol* 2016;34:3325-3345. ²Check DK, *et al. J Pain Symptom Manage* 2022;63(4):e397-e416. ³Jiang C, *et al. JAMA Oncology* 2019;E1-E2.



Shifting Practices and Guidelines

Opioids in the Palliative Care Oncology Space¹

Recognition of prevalence of aberrant behaviors (non-medical opioid use) Recognition of potential harms from opioids Recognition of 'blurring of lines' between malignancyrelated pain, chronic pain Reduction in prescribed opioids Oncologists,² 2013-2017: -20% US total,³ 2013-2017: -26% Calls for universal screening (via risk stratification tools, potentially UDS) ¹ Dalal S, Bruera E. 2019 ASCO Educational Book; 24-35. ² Enzinger AC, Wright AA. / Natl Cancer Inst 2021;113:225-226.

³ <u>https://www.fda.gov/files/about%20fda/published/FDA-Analysis-of-</u> Long-Term-Trends-in-Prescription-Opioid-Analgesic-Products--Quantity--

<u>Sales--and-Price-Trends.pdf</u>; accessed 23 Oct 2021

Less Opioids Prescribed for Inpatients With Advanced Cancer

Patterns of Opioid Prescription, Use, & Costs Among **Patients With Advanced Cancer & Inpatient Palliative**

N=7**C**#,rep**Brieves** enth**290%**a**8c**2**014** cancer who received PC consult

Median age 57; 55% women; 61% white

12% had history of illicit drug use ESAS pain score 6.0 (of 10) at admission

MLOS 5d; median time to consult 1d

ESAS pain score 5.0 on discharge Median f/u in outpt PC clinic 13d

	<u>2008</u>	2014	change				
OME at admissi	on 60	50	-16%				
Daily OME (PC c		83	-45%				
OME at discharg	ge 75	60	-20%				
Total opioids Rx The evidence su		221 B	+2%				
palliative consultants became							
reluctant to escalate dosing in the inpatient setting for severely ill							

Yennurajalingam S, et al. J Oncology Practice 2018,15(1) 274-e83.

Fewer Opioids Prescribed for Patients With Advanced Cancer, and It's Not Risk-Stratified

Has Declining Opioid Dispensing to Cancer Patients Been Tailored to Risk of Opioid Harms?

N=32,789;	<u>Variable</u>		<u>20</u>	<u>800</u>	<u>2018</u>	<u>Change</u>	
claims data	≥1 opioid fil	ll per 90d	30% ¹	20%	-33%		
analysis	Daily OME (those on Rx)	65	41	-38%		
Patients ≥18	High-dose F	Rx (≥90 OME) ²	35%1	5%	-55%		
УO	Concurrent	opioid/BZD	21	20%	-5%		
, breast (72%),	Rx ³	%	78	51	-34%		
colorectal	Opioids Rx/	100 in US ⁴	¹ 82% in those with				
colorectal Comparison of 2018 Same decimes in Rx	, 2008 data s	howed	OU				
same declines in Rx	rates for pati	ents			ose with		
with without SUD/O	UD/mental h	lealth	0U 3P7		ad to MCP		
Neck(, 5%) With Without SUD/OUD/mental health Sarcoma (2%) Glagnosis Hig evidence suggests that those treating cancer overage in 2013 reduced onicid treatment at about the same rat ⁴ CDC gover							
reduced opioid treatment at about the same rate GBG govon-							
oncology settings, and that they do not risk-stratify Rx strategies							
Townsend TN, et al. J Pain Symptom Manage 2022;63(2):179-188.							

OUD Patient With Cancer? No Additional Opioids for You, Unless Pain Specialist Is Consulted

Compassion Inequities & OUD: A Matched Case-Control Analysis Examining Ipatient Management of Cancer-Related Pain for Patients with OUD

West Virginia; 80 hospitalizations N=25 pts with OUD; 31 pts without Median age: 38 yo **Median survival:**

OUD ptsnon-OUD pts55% male55% femaleAdmit/PM: -3 OMEAdmit/PM: +37 OME58% PC consult20% PCconsult20% PC+27% OME w/PM+27% OME w/PMlikely to receive dose escalation ofopioids on admission, regardless ofOUD remission status.


One are mossible on TPN; denied IV opioids for 'drug-seeking behavior.' She died 7 days later.

Singh SA, et al. J Pain Symptom Manage 2021;62(3):e156-e163.



Going to Hospice? Less Opioids for You

Decreasing Trends in Opioid Prescribing on Discharge to Hospice Care Oregon (550-bed hospital);



Furono JP, et al. J Pain Symptom Manage 2021;62(5):1026-1033.

<u>When You Drain the</u>

- Survivors face difficulty in procuring opioid treatment³
- Patients in treatment, survivors have employment,
- 1 Shi Q, fiplaquiat cliffic utiles 2779-2790.
- ² Sanford NN, et al. Cancer 2019;125(23):4310-4315.
 ³ Nijs J, et al. Pain Physician 2021;24(5):309-317. Jensen UMP, Qtal. Pain Physician 2021;24(5):309-317. Jensen UMP, Qtal. Pain Physician 2021;24(5):309-1106. Davidsen M, et al. Scan J Public Health 2011;39(7 Suppl):131-35. van den Beuken-van Everdingen MH, et al. J Pain Symptom Manage 2016;51:1070-1090. Schenker Y, Merlin JS, Quill TE. JAMA 2018;320(9): 871-2.
- ⁴ Halpern MT, de Moor JS, Yabroff R. J Clin Oncol 2021;40:24-41.







Meet Monique, Who Lives on the Business End of Unintended Consequences

Metastatic breast cancer

Limited supply on hand at pharmacies

eRx cannot be transferred

Pharmacies will not reveal supplies

Social determinants of health

Frequent prejudicial 'treatment'

Having pain while being black






A Modest Proposal: the Middle & the Margins

Licit Opioid Use **Professional education Professional regulation SUD Treatment** Harm MAT Reduction Chronic Use (1-5%) **Primary Prevention** Sober housing Needle **Early Life Intervention** Addiction (8%) Vocational rehab exchange **Public Education Peer support** Reversal Illicit Opioid Use (4%?) agents Interdiction Legal deterrents

proactive long-term changes ROI difficult to measure proactive and reactive intermediate changes ROI simpler to measure

reactive short-term changes ROI simple to measure The best time for planting a tree is 20 best time is now.

Chinese proverb



Public Comment

 Does anyone wish to comment or address the Opioid Abatement Council?

In-Person: please raise your hand

Virtual: please click the "**raise your hand**" icon located on the top menu bar (3rd from the left)

